NCT06279351RecruitingPhase 2
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 14 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application. 2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- First submitted
- 17 Dec 2023
- Start date
- 11 Aug 2024
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Xinqiao Hospital of Chongqing
- Diseases
- Colorectal cancer
- NCT number
- NCT06279351
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 96
- From 11 Aug 2024 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with severe dysfunction of vital organs (heart, liver, kidney);
- Patients with other malignant tumors;
- In the active phase of acute or chronic infectious diseases;
- People with a clear history of drug allergy or allergic constitution;
- Other conditions in which the patient was considered inappropriate to participate in the study.
Age
- Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);
Other
- Patients participating in other clinical trials;
Who the study is looking for
- Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing;
- Physical state is good: PS 0-2;
- Expected survival of more than 3 months;
- Aged 18-75 years old;
- Have not received systematic chemotherapy before;
- Did not receive cetuximab treatment;
- Liver, kidney and bone marrow functions are basically normal;
- The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;
- Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| the second affiliated hospital of Army medical university Coordinator of this site? Confirm its status | Chongqing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.